We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Genomic Prostate Score Test Evaluated as Prognosis Predictor

By LabMedica International staff writers
Posted on 13 Jul 2020
Molecular assays, including multi-gene expression assays, are increasingly used clinically to improve risk stratification for men with newly diagnosed prostate cancer (PCa). More...


The problem for men with unfavorable intermediate (UFI)-risk PCa is that until now, the lack of definitive knowledge about this particular subtype has made it almost impossible to opt for active surveillance, despite the fact that some of them end up with less aggressive disease.

Cancer specialist at the Case Western Reserve University (Cleveland, OH, USA) and their colleagues analyzed the associations multi-gene expression assay with results with biochemical recurrence (BCR), distant metastases (DM) and prostate-specific death (PCD) in two cohorts of men with UFI prostate cancer who were treated with radical prostatectomy. The analyses included 299 intermediate-risk prostate patients, 175 of whom had UFI-risk disease; 103 from the Kaiser Permanente Northern California (KPNC) cohort and 72 from the Center for Prostate Disease Research (CDPR) cohort.

The assay used in the study was the Oncotype DX Genomic Prostate Score (GPS), (Genomic Health, Inc, Redwood City, CA, USA). The test is a quantitative reverse transcriptase polymerase chain reaction assay that measures the expression levels of 17 genes (12 cancer-related and five reference) in messenger RNA extracted from microdissected tumor tissue obtained from fixed prostate needle biopsies. It provides a GPS result scaled from 0 to 100 as a molecular measure of increasing tumor aggressiveness. It has been analytically and clinically validated as a significant independent predictor of multiple endpoints in men with newly diagnosed low and intermediate risk PCa.

The scientists reported that the GPS result as a dichotomous value (≤40 versus >40) was a significant predictor of BCR in UFI patients in multivariate analyses (hazard ratio [HR] 6.0; 95% confidence interval [CI] 2.0-22.4). The GPS result was a strong predictor of all three endpoints in multivariate analyses: BCR = HR 7.1; DM HR= 5.4; PCD HR =3.4. UFI patients with GPS >40 had outcomes consistent with high-risk disease, whereas UFI patients with GPS ≤40 had outcomes similar to FI risk patients (CPDR/KPNC).

Jennifer Cullen, PhD, MPH, an Associate Professor and the lead author of the study, said, “No one had focused specifically on unfavorable intermediate. And that's important because there is a gray zone, a very murky area, in knowing how aggressively to treat that disease, because we don't know if it's going to behave more like high-risk disease or more like favorable intermediate-risk disease. You are always trying to strike a careful balance between preserving oncologic outcome and sparing patients decrements in quality of life. So, there's this very careful discussion and balance that patients and doctors have to strike in deciding what treatment course to pursue for men in that gray zone.”

The authors concluded that the GPS result was a strong independent predictor of BCR, DM, and PCD in intermediate risk prostate cancer. UFI patients with GPS >40 have a poor prognosis and may benefit from additional therapeutic options. The study was published on June 7, 2020 in the journal Urology.

Related Links:
Case Western Reserve University
Genomic Health



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.